Skip to main content

Table 4 Hazard ratios for overall survival 1, 2 and 5 years after start of [ 90 Y-DOTA]-TOC Therapy ( n = 359 )

From: Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

   1-YEAR SURVIVAL 2-YEARS SURVIVAL 5-YEARS SURVIVAL
Covariate   Hazard ratio (95% CI)* P Value Hazard ratio (95% CI)* P Value Hazard ratio (95% CI)* P Value
Gender (male vs. females) 1.00 (0.61-1.63) 0.99 1.08 (0.75-1.57) 0.66 1.00 (0.75-1.35) 0.98
Age (per 10 years) 1.00 (0.98-1.02) 0.69 0.99 (0.98-1.00) 0.19 1.00 (0.99-1.01) 0.83
Duration of Disease (per year) 0.94 (0.86-1.04) 0.22 0.93 (0.86-0.99) 0.03 0.97 (0.93-1.01) 0.16
Previous Surgery (vs. no surgery) 0.59 (0.33-1.04) 0.07 0.57 (0.38-0.87) 0.009 0.63 (0.45-0.87) 0.006
Previous Chemotherapy (vs. no chemotherapy) 1.28 (0.75-2.19) 0.37 1.28 (0.86-1.93) 0.23 1.68 (1.21-2.32) 0.002
Previous Radiation (vs. no radiation) 0.63 (0.31-1.31) 0.22 0.75 (0.45-1.25) 0.27 0.93 (0.62-1.39) 0.72
Solitary Metastases (vs. multiple metastases) 0.38 (0.11-1.37) 0.14 0.60 (0.22-1.60) 0.31 0.63 (0.29-1.38) 0.25
Liver Metastases (vs. no liver metastases) 1.83 (0.68-4.95) 0.24 1.40 (0.68-2.92) 0.36 1.57 (0.88-2.80) 0.13
Bone Metastases (v. no bone metastases) 1.59 (0.90-2.81) 0.11 1.18 (0.74-1.87) 0.49 1.38 (0.94-2.01) 0.10
Tumor Uptake Score 2 (vs. uptake score 1) 1.47 (0.35-6.14) 0.60 2.10 (0.69-6.42) 0.19 0.77 (0.31-1.92) 0.58
Tumor Uptake Score 3 (vs. uptake score 1) 0.51 (0.13-2.09) 0.35 0.85 (0.28-2.61) 0.78 0.40 (0.16-0.98) 0.05
Low Dose [90Y-DOTA]-TOC (vs. High Dose) 0.93 (0.19-4.58) 0.93 0.39 (0.13-1.19) 0.10 0.39 (0.16-0.96) 0.04
Intermediate Dose [90Y-DOTA]-TOC (vs. High Dose) 0.74 (0.24-2.31) 0.61 0.52 (0.25-1.11) 0.09 0.57 (0.33-0.99) 0.05
  1. *Estimates for each co-variable have been adjusted for histology as a categorical co-variable, for the cumulative [90Y-DOTA]-TOC activity as well as for all other co-variables listed.